26 Years of LDL - Apheresis: A review of experience

Transfusion and Apheresis Science

Volumn 41, Issue 1, 2009, Pages 49-59

  Borberg, H ^a  

^a Deutsches Hamapherese Zentrum   (Germany)

Author keywords

Apheresis therapy; Cholesterol; Cholesterol lowering therapy; Familial hypercholesterolaemia; LDL Apheresis; LDL cholesterol; LDL elimination

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; BONE PAIN; DRUG HYPERSENSITIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; GERMANY; HAIR LOSS; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; MUSCLE WEAKNESS; MYALGIA; PLEIOTROPY; PSEUDOALLERGIC REACTION; QUALITY CONTROL; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CHROMATOGRAPHY, AFFINITY; EQUIPMENT DESIGN; EQUIPMENT REUSE; FEMALE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE;

EID: 67651225924     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2009.05.013     Document Type: Article

References (39)

1. ANCEP Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227
2. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., and Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995) 488-493
3. Baigent C., et al. Efficacy, safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267
4. Bláha M., Pecka M., Urbánková J., Bláha V., Malý J., Zadák Z., et al. Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia. Transfus Apher Sci 30 2 (2004) 83-87
5. Bláha M., Krejsek J., Bláha V., Andrýs J., Vokurková D., Malý J., et al. Selectins and monocyte chemotactic peptide as markers of atherosclerosis activity. Physiol Res 53 (2004) 273-278
6. Bláha M, Cermanová M, Bláha V, Jarolím P, Andrýs C, Blažek M, et al. Changes in endoglin levels during extracorporeal elimination therapy for familial hyperlipoproteinemia. Atherosclerosis; in press.
7. Blaha M., Masin V., Stransky P., Blaha V., Cermanova M., Maly J., et al. Optimization of the therapeutic procedure during LDL-apheresis - a computerized model. Transfus Apher Sci 32 2 (2005) 149-156
8. Borberg H., Stoffel W., and Oette K. The development of specific plasmaimmunoadsorption. Plasma Ther Transfus Technol 4 4 (1983) 459-466
9. Borberg H. The development of an automated therapeutic immunoadsorption system using the LDL-apheresis model. Europ J Clin Invest 13 II (1983) A39
10. Borberg H., Gaczkowski A., Hombach V., Oette K., and Stoffel W. Treatment of familial hypercholesterolaemia by means of specific immunoadsorption. J Clin Apher 4 (1988) 59-65
11. Borberg H, Oette K. Experience with and conclusions from three trials on LDL-apheresis. In: Agishi T et al., editor. Therapeutic plasmapheresis (XII). Utrecht: VSP BV (Publ.); 1993. p. 13-20.
12. Borberg H, Oette K. Outlooks in LDL-apheresis. In: Koenig W, Hombach V, Bond MG, Kramsch DM, editors. Progression and regression of atherosclerosis. Blackwell Wissenschaft, Wien (Publ.); 1995. p. 306-18. .
13. Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., et al. Explaining the decrease in US deaths from coronary disease 1980-2000. N Engl J Med 356 23 (2007) 2388-2398
14. DeGennes J.L., Maunand B., and Maunand B. Formes homozygotes cutaneo-tendineuses de xanthomatose hypercholesterolemique dans une observation familiale exemplaire-essai de plasmapherese a titre du traitement heroique. Bulletins et Memoires de la Société Médicale des Hopitaux de Paris 118 (1967) 1377-1387
15. Freudenhammer Ch. Untersuchungen zur Biokompatibilität der LDL-Apherese. Aktivierung von Monozyten und neutrophilen Granulozyten. Thesis, Medizinische Fakultät der Universität Köln; 1995.
16. Genser B., and März W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 95 8 (2006) 393-404
17. Hombach V., Borberg H., Gaczkowski A., Oette K., and Stoffel W. Regression der Koronarsklerose bei familiärer Hyperchoelsterinämie Typ IIa durch spezifische LDL-Apherese. Dtsch Med Wschr 45 (1986) 1709-1715
18. Hummelsheim T., Borberg H., Brunner R., and Oette K. Acute changes of haemorheological parameters by LDL-apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 22 Suppl. 1 (1995) 42-44
19. Kadar J.G., Späth P.J., Gaczkowski A., Oette K., Stoffel W., and Borberg H. Biocompatibility studies on a clinically well tolerated extracorporeal system. Plasma Ther Transfus Technol 8 (1988) 307-318
20. Kadar JG. Biocompatibility studies during specific immunoadsorption. In: Second international congress world aph assoc, Ottawa; May 18th-20th, 1988. Abstract vol. p. 9.
21. Knisel W., Di Nicuolo A., Pfohl M., Müller H., Risler H., Eggstein M., et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system. J Intern Med 234 (1993) 479-487 Abstract
22. Laatikainen T., Critchley J., Vartiainen E., Salomaa V., Ketonen M., and Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epid 162 (2005) 764-773
23. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 7404 (2003) 1407-1423
24. Lupien P.J., Moorjani S., and Awad J. A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1 7972 (1976) 1261-1265
25. 0'Driscoll G., Green D., and Taylor R.R. Simvastatin, a HMG-coenzyme A reductase inhibitor improves endothelial dependent vasodilatation in hypercholesteroaemic humans. Circulation 95 (1997) 76-82
26. Oette K., and Borberg H. Variables in regression of atherosclerosis in familial hypercholesterolaemic patients under longterm LDL-apheresis. Plasma Ther Transfus Technol 9 (1988) 17-23
27. Otto C., Baumann M., Schreiner T., Bartsch G., Borberg H., Schwandt P., and Schmid-Schönbein H. Standardized ultrasound as a new method to induce platelet aggregation. Eur J Ultrasound 14 2-3 (2001) 157-166
28. Otto C., Geiss H.C., Empen K., and Parhofer K.G. Longterm reduction of C-reactive protein concentration by regular LDL-apheresis. Atherosclerosis 174 (2004) 151-156
29. Parusel M. Untersuchungen zur Biokompatibilität der LDL-Apherese. Interaktionen zwischen der Anti-Apolioprotein-B IgG-Sepharose 4B cl, dem Komplementsystem und den Blutzellen Thesis, University of Köln; 1994.
30. Richter W.O., Jacob B.G., Ritter M., Sühler K., Sühler K., Vierneisel K., et al. 3 year treatment of familial heterozygous hypercholesterolaemia by extracorporeal LDL- immunoadsorption with poly clonal apolipoprotein B antibodies. Metabolism 42 (1993) 888-894
31. Richter WO, Schwandt P. In: Handbuch der Fettstoffwechselstörungen. Schwandt, Richter (Hrsg.). Schattauer Verlag; 1995. p. 682-90.
32. Schuff-Werner P., Schütz E., Seyde W.C., Eisenhauer T., Jannings G., Armstrong W., et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin induced extracorporeal LDL-precipitation. Eur J Invest 19 (1989) 30-37
33. Stefanec GM. Prädiktionsparameter extrakorporaler Eliminationstherapien am Modell der LDL-Apherese, Dissertation, Medizinische Fakultät der Universität Köln; 1999.
34. Stoffel W., and Demant T. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Nat Acad Sci 78 (1981) 611-615
35. Stoffel W., Borberg H., and Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet II (1981) 1005-1007
36. Thompson G.R., Lowenthal R., and Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1 7918 (1975) 1208-1211
37. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
38. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., and Imaizumi T. Single LDL-apheresis improves endothelial dependent vasodilatation in hypercholesterol aemic humans. Circulation 95 (1997) 76-82
39. Waidner T., Franzen D., Voelker W., Ritter M., Borberg H., Hombach V., et al. The effect of LDL-apheresis on progression of coronary artery disease in patients with familial hypercholesterolaemia. Results of a multicenter LDL-apheresis study. Clin Investig 72 (1994) 858-863 (for the LDL-Apheresis Study Group)